Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (DE:HTD)
BERLIN:HTD
Corcept Therapeutics (HTD) Stock Price & Analysis
1 Followers
HTD Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€19.40 - €31.60
Previous Close€23.45
Volume485.00
Average Volume (3M)251.00
Market Cap
€2.31B
Enterprise Value€1.97B
Total Cash (Recent Filing)$368.22M
Total Debt (Recent Filing)$151.00K
Price to Earnings (P/E)N/A
Beta-0.04
Next Earnings
May 02, 2024EPS Estimate
€0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding103,517,388
10 Day Avg. Volume0
30 Day Avg. Volume251
Standard Deviation0.16
R-Squared0.06
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)5.15
Price to Sales (P/S)13.76
Price to Cash Flow (P/CF)110.80
P/FCF Ratio110.80
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.08
Enterprise Value/Gross Profit4.14
Enterprise Value/Ebitda16.72
Forecast
1Y Price Target
€35.91Price Target Upside53.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Corcept Therapeutics News
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.05% Other Institutional Investors
99.95% Public Companies and
Individual Investors
HTD FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was €19.40 and its highest was €31.60 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Currently, no data Available
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is May 02, 2024 which is in 14 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 15, 2024. The company reported €0.258 earnings per share for the quarter, beating the consensus estimate of €0.238 by €0.02.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is €0.21.
How many shares outstanding does Corcept Therapeutics Inc. have?
Currently, no data Available
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of €0.258 in its last earnings report, beating expectations of €0.238. Following the earnings report the stock price went down -6.195%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Among the largest hedge funds holding Corcept Therapeutics Inc.’s share is Royce & Associates LLC. It holds Corcept Therapeutics Inc.’s shares valued at 11M.
---
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€35.91 (53.15% Upside)
€35.91 (53.15% Upside)
Blogger Sentiment
Bullish
DE:HTD Sentiment 75%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
8.70%
12-Months-Change
Fundamentals
Return on Equity
20.92%
Trailing 12-Months
Asset Growth
6.53%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
---
HTD Earnings Call
Q4 2024
0:00 / 0:00
---
HTD Stock 12 Months Forecast
Average Price Target
€35.91
▲(53.15% Upside)
Technical Analysis
Corcept Therapeutics
―
Insmed
―
Karyopharm Therapeutics
―
Pfizer
―
Supernus Pharmaceuticals
―
Best Analysts Covering HTD
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+8.07%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +8.07% per trade.
---